卡泊珠单抗治疗获得性血栓性血小板减少性紫癜（大力神试验）。
Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura (HERCULES trial).
作者信息
Estcourt L J
机构信息
Radcliffe Department of Medicine and BRC Haematology Theme, John Radcliffe Hospital, Oxford, UK.
NHS Blood and Transplant, Oxford Centre, John Radcliffe Hospital, Oxford, UK.
出版信息
Transfus Med. 2019 Jun;29(3):146-148. doi: 10.1111/tme.12615.
CLINICAL QUESTION
In people with acquired thrombotic thrombocytopenic purpura (TTP), does caplacizumab decrease the time to normalisation of the platelet count and the risk of death and complications caused by thrombotic events and organ damage?
EVIDENCE FROM TRIAL
In adults with acquired TTP, caplacizumab decreased the time to normalisation of the platelet count and decreased the risk of TTP-related death and recurrence of TTP.
临床问题
在获得性血栓性血小板减少性紫癜（TTP）患者中，卡泊单抗是否能缩短血小板计数恢复正常的时间，并降低由血栓事件和器官损伤导致的死亡及并发症风险？
试验证据
在获得性TTP的成人患者中，卡泊单抗缩短了血小板计数恢复正常的时间，并降低了TTP相关死亡和TTP复发的风险。
Zotero 插件